Results 251 to 260 of about 212,261 (297)

CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer. [PDF]

BMC Med Imaging
Xu T, Liu X, Chen Y, Wang S, Jiang C, Gong J.   +5 more
europepmc   +1 more source

Iatrogenic Pituitary Shutdown: A Rare Adverse Event of Programmed Cell Death-Ligand 1 Inhibitor. [PDF]

JCEM Case Rep
Al-Hiari M, Workman A, Ezeh E, Teka S.
europepmc   +1 more source

Cytotoxic T-lymphocyte antigen 4 and programmed cell death ligand 1 blockade increases the effectiveness of interleukin-15 immunotherapy in a bovine leukemia model. [PDF]

Vet World
Mukantayev K, Tursunov K, Adish Z, Kanayev D, Tokhtarova L, Nurtleu M, Abirbekov B.   +6 more
europepmc   +1 more source

Establishing a new human lung squamous cell carcinoma cell line, OMUL-1, expressing insulin-like growth factor 1 receptor and programmed cell death ligand 1. [PDF]

Thorac Cancer
Nagamine H, Yashiro M, Mizutani M, Sugimoto A, Matsumoto Y, Tani Y, Kaneda H, Yamada K, Watanabe T, Asai K, Suzuki S, Kawaguchi T.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Programmed death ligand 1 signals in cancer cells

Nature Reviews Cancer, 2022
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to develop effective and revolutionary immunotherapies using antibodies blocking these cell-extrinsic interactions.
Anand V. R. Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel   +2 more
openaire   +2 more sources

Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors

Expert Opinion on Biological Therapy, 2021
Introduction: In the past few years, administrating monoclonal humanized antibodies, namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand (PD-L1), has yielded reassuring tumor regression rates. Anti-PD-1/PD-L1 checkpoint inhibitors disrupt the engagement of PD-1 on T-cells and their ligands on tumor or other ...
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei   +2 more
openaire   +2 more sources

Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts

Journal of the American Academy of Dermatology, 2019
Cutaneous warts have high prevalence and cause significant morbidity. Understanding the mechanisms by which warts evade the immune system could lead to targeted and improved treatments.To determine whether cutaneous warts express programmed cell death ligand 1 (PD-L1) and to characterize the expression of programmed cell death 1 (PD-1) within the ...
Wesley Y, Yu, Timothy G, Berger, Jeffrey P, North, Zoltan, Laszik, Jarish N, Cohen   +4 more
openaire   +2 more sources

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Journal of Medicinal Chemistry, 2018
The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include production difficulties ...
Tianyu Wang, Xiaoxing Wu, Changying Guo, Kuojun Zhang, Jinyi Xu, Zheng Li, Sheng Jiang   +6 more
openaire   +2 more sources

Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy

Recent Patents on Anti-Cancer Drug Discovery, 2016
Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could
Xiao-Na, Fang, Li-Wu, Fu
openaire   +2 more sources